Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2

The present exploratory analysis examined the efficacy, safety, and quality-of-life effects of everolimus (EVE) + exemestane (EXE) in the subgroup of patients in BOLERO-2 whose last treatment before study entry was in the (neo)adjuvant setting. In BOLERO-2, patients with hormone-receptor-positive (H...

Descripción completa

Detalles Bibliográficos
Autores principales: Beck, J. Thaddeus, Hortobagyi, Gabriel N., Campone, Mario, Lebrun, Fabienne, Deleu, Ines, Rugo, Hope S., Pistilli, Barbara, Masuda, Norikazu, Hart, Lowell, Melichar, Bohuslav, Dakhil, Shaker, Geberth, Matthias, Nunzi, Martina, Heng, Daniel Y. C., Brechenmacher, Thomas, El-Hashimy, Mona, Douma, Shyanne, Ringeisen, Francois, Piccart, Martine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907668/
https://www.ncbi.nlm.nih.gov/pubmed/24362951
http://dx.doi.org/10.1007/s10549-013-2814-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907668/
https://www.ncbi.nlm.nih.gov/pubmed/24362951
http://dx.doi.org/10.1007/s10549-013-2814-5

Ejemplares similares